Epithelial mesenchymal transition in aggressive lung cancers

Research output: Chapter in Book/Report/Conference proceedingChapter

The progression of a cancer cell into a metastatic entity contributes to more than 90 % of cancer related deaths. Therefore, the prevention and treatment of metastasis is an unmet clinical need. Epithelial to mesenchymal transition (EMT) is an evolutionary conserved developmental program, which is induced during cancer progression and contributes to metastatic colonization. EMT endows metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit therapeutic resistance. The disseminated tumor cells recruited to distant organs are suggested to subsequently undergo an EMT reversion through mesenchymal to epithelial transition (MET), necessary for effi cient colonization and macrometastasis. A major focus of cancer research is to determine the cellular and molecular mechanisms underlying EMT/MET in tumor invasion, dissemination and metastasis. In this chapter, we will focus on the contribution of the EMT signaling pathways in lung cancer progression, cancer stem cells and acquired resistance to EGFR tyrosine kinase inhibitors and chemotherapy. We will also discuss the potential of targeting EMT pathways as an attractive strategy for the treatment of lung cancer.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York
Pages37-56
Number of pages20
Volume890
DOIs
StatePublished - Oct 1 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume890
ISSN (Print)00652598
ISSN (Electronic)22148019

PMID: 26703798

Altmetrics

Cite this

Standard

Epithelial mesenchymal transition in aggressive lung cancers. / Mittal, Vivek.

Advances in Experimental Medicine and Biology. Vol. 890 Springer New York, 2016. p. 37-56 (Advances in Experimental Medicine and Biology; Vol. 890).

Research output: Chapter in Book/Report/Conference proceedingChapter

Harvard

Mittal, V 2016, Epithelial mesenchymal transition in aggressive lung cancers. in Advances in Experimental Medicine and Biology. vol. 890, Advances in Experimental Medicine and Biology, vol. 890, Springer New York, pp. 37-56. https://doi.org/10.1007/978-3-319-24932-2_3

APA

Mittal, V. (2016). Epithelial mesenchymal transition in aggressive lung cancers. In Advances in Experimental Medicine and Biology (Vol. 890, pp. 37-56). (Advances in Experimental Medicine and Biology; Vol. 890). Springer New York. https://doi.org/10.1007/978-3-319-24932-2_3

Vancouver

Mittal V. Epithelial mesenchymal transition in aggressive lung cancers. In Advances in Experimental Medicine and Biology. Vol. 890. Springer New York. 2016. p. 37-56. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-24932-2_3

Author

Mittal, Vivek. / Epithelial mesenchymal transition in aggressive lung cancers. Advances in Experimental Medicine and Biology. Vol. 890 Springer New York, 2016. pp. 37-56 (Advances in Experimental Medicine and Biology).

BibTeX

@inbook{09dd860a0f8348ca99f3f844953553f1,
title = "Epithelial mesenchymal transition in aggressive lung cancers",
abstract = "The progression of a cancer cell into a metastatic entity contributes to more than 90 {\%} of cancer related deaths. Therefore, the prevention and treatment of metastasis is an unmet clinical need. Epithelial to mesenchymal transition (EMT) is an evolutionary conserved developmental program, which is induced during cancer progression and contributes to metastatic colonization. EMT endows metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit therapeutic resistance. The disseminated tumor cells recruited to distant organs are suggested to subsequently undergo an EMT reversion through mesenchymal to epithelial transition (MET), necessary for effi cient colonization and macrometastasis. A major focus of cancer research is to determine the cellular and molecular mechanisms underlying EMT/MET in tumor invasion, dissemination and metastasis. In this chapter, we will focus on the contribution of the EMT signaling pathways in lung cancer progression, cancer stem cells and acquired resistance to EGFR tyrosine kinase inhibitors and chemotherapy. We will also discuss the potential of targeting EMT pathways as an attractive strategy for the treatment of lung cancer.",
keywords = "Cancer stem cells, Epithelial mesenchymal transition, Lung cancer, Metastasis, Resistance, Therapy",
author = "Vivek Mittal",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/978-3-319-24932-2_3",
language = "English (US)",
volume = "890",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York",
pages = "37--56",
booktitle = "Advances in Experimental Medicine and Biology",
address = "United States",

}

RIS

TY - CHAP

T1 - Epithelial mesenchymal transition in aggressive lung cancers

AU - Mittal, Vivek

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The progression of a cancer cell into a metastatic entity contributes to more than 90 % of cancer related deaths. Therefore, the prevention and treatment of metastasis is an unmet clinical need. Epithelial to mesenchymal transition (EMT) is an evolutionary conserved developmental program, which is induced during cancer progression and contributes to metastatic colonization. EMT endows metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit therapeutic resistance. The disseminated tumor cells recruited to distant organs are suggested to subsequently undergo an EMT reversion through mesenchymal to epithelial transition (MET), necessary for effi cient colonization and macrometastasis. A major focus of cancer research is to determine the cellular and molecular mechanisms underlying EMT/MET in tumor invasion, dissemination and metastasis. In this chapter, we will focus on the contribution of the EMT signaling pathways in lung cancer progression, cancer stem cells and acquired resistance to EGFR tyrosine kinase inhibitors and chemotherapy. We will also discuss the potential of targeting EMT pathways as an attractive strategy for the treatment of lung cancer.

AB - The progression of a cancer cell into a metastatic entity contributes to more than 90 % of cancer related deaths. Therefore, the prevention and treatment of metastasis is an unmet clinical need. Epithelial to mesenchymal transition (EMT) is an evolutionary conserved developmental program, which is induced during cancer progression and contributes to metastatic colonization. EMT endows metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit therapeutic resistance. The disseminated tumor cells recruited to distant organs are suggested to subsequently undergo an EMT reversion through mesenchymal to epithelial transition (MET), necessary for effi cient colonization and macrometastasis. A major focus of cancer research is to determine the cellular and molecular mechanisms underlying EMT/MET in tumor invasion, dissemination and metastasis. In this chapter, we will focus on the contribution of the EMT signaling pathways in lung cancer progression, cancer stem cells and acquired resistance to EGFR tyrosine kinase inhibitors and chemotherapy. We will also discuss the potential of targeting EMT pathways as an attractive strategy for the treatment of lung cancer.

KW - Cancer stem cells

KW - Epithelial mesenchymal transition

KW - Lung cancer

KW - Metastasis

KW - Resistance

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84951873357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951873357&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-24932-2_3

DO - 10.1007/978-3-319-24932-2_3

M3 - Chapter

VL - 890

T3 - Advances in Experimental Medicine and Biology

SP - 37

EP - 56

BT - Advances in Experimental Medicine and Biology

PB - Springer New York

ER -

Similar Experts

Similar Research Outputs Profiled Experts

Similar research outputs

Similar Research Outputs

  1. The microenvironment of lung cancer and therapeutic implications

    Mittal, V., El Rayes, T., Narula, N., McGraw, T. E., Altorki, N. K. & Barcellos-Hoff, M. H., Oct 1 2016, Advances in Experimental Medicine and Biology. Springer New York, Vol. 890. p. 75-110 36 p. (Advances in Experimental Medicine and Biology; vol. 890).

    Research output: Chapter in Book/Report/Conference proceedingChapter

ID: 18795859